Recursion Pharmaceuticals Inc (NASDAQ: RXRX) kicked off on Monday, down -2.59% from the previous trading day, before settling in for the closing price of $6.94. Over the past 52 weeks, RXRX has traded in a range of $4.97-$15.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 132.77% over the last five years. While this was happening, its average annual earnings per share was recorded 1.11%. With a float of $226.82 million, this company’s outstanding shares have now reached $291.36 million.
In terms of profitability, gross margin is -26.05%, operating margin of -824.25%, and the pretax margin is -767.94%.
Recursion Pharmaceuticals Inc (RXRX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Recursion Pharmaceuticals Inc is 22.15%, while institutional ownership is 76.19%. The most recent insider transaction that took place on Oct 15 ’24, was worth 76,326. In this transaction Director of this company sold 11,447 shares at a rate of $6.67, taking the stock ownership to the 7,089,007 shares. Before that another transaction happened on Oct 17 ’24, when Company’s Former BOD proposed sale 404,688 for $6.66, making the entire transaction worth $2,693,813.
Recursion Pharmaceuticals Inc (RXRX) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.43 earnings per share (EPS), lower than consensus estimate (set at -0.38) by -0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to -43.41% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Take a look at Recursion Pharmaceuticals Inc’s (RXRX) current performance indicators. Last quarter, stock had a quick ratio of 6.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 39.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.72 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Analysing the last 5-days average volume posted by the [Recursion Pharmaceuticals Inc, RXRX], we can find that recorded value of 3.91 million was lower than the volume posted last year of 5.76 million. As of the previous 9 days, the stock’s Stochastic %D was 69.57%. Additionally, its Average True Range was 0.38.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 21.32%, which indicates a significant decrease from 70.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.46% in the past 14 days, which was lower than the 75.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.70, while its 200-day Moving Average is $8.77. Now, the first resistance to watch is $6.94. This is followed by the second major resistance level at $7.11. The third major resistance level sits at $7.29. If the price goes on to break the first support level at $6.59, it is likely to go to the next support level at $6.41. Now, if the price goes above the second support level, the third support stands at $6.24.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
The company with the Market Capitalisation of 1.97 billion has total of 237,664K Shares Outstanding. Its annual sales at the moment are 44,580 K in contrast with the sum of -328,070 K annual income. Company’s last quarter sales were recorded 14,420 K and last quarter income was -97,540 K.
